Medi­vir out-li­cens­es hep C drug to Chi­na’s As­cle­tis; Cel­lec­tis launch­es pi­o­neer­ing UCART123 US study

⇨ As­cle­tis has in-li­censed the Chi­nese mar­ket rights for Stock­holm-based Medi­vir’s NS5B in­hibitor for hep C. Terms weren’t dis­closed but Hangzhou-based As­cle­tis gets an­oth­er piece of the puz­zle for a cock­tail that can cure hep C, which it plans to hus­tle to reg­u­la­tors.

⇨ Cel­lec­tis $CLLS says they’ve dosed the first pa­tient in their pi­o­neer­ing US hu­man study of the first off-the-shelf CAR-T tar­get­ing CD123. The study of UCART123 is be­ing car­ried out by in­ves­ti­ga­tors at MD An­der­son in Hous­ton.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.